CSF2 and Alzheimer disease: A phase 2 RCT of recombinant human GM-CSF in participants with mild-to-moderate AD showed that subcutaneous injection of sargramostim (5 days/week for 3 weeks) was safe, associated with reduced plasma biomarkers of neuronal damage/neurodegeneration, and improved cognition based on MMSE scores [104].